Frontiers in surgery · 2026
Poly-L-lactic acid (PLLA) in arm contouring: a prospective and blinded trial of Rennova® Elleva and Sculptra®.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bravo Bruna Souza Felix, de Souza Ana Luisa Leopoldino, Barreiro Emmanuela Beatriz Vantini, Vilar Airá Novello, Gouvea Bárbara Fouraux, Bravo Leonardo Gonçalves, Neves Marina Ramos Baeta
Аннотация
BACKGROUND: Poly-L-lactic acid (PLLA) is a biostimulatory filler used to improve dermal laxity and contour, yet comparative data between formulations for upper-arm rejuvenation remain scarce.
METHODS: In this prospective, randomized, blinded split-arm trial, 20 adults received bilateral upper-arm injections with two PLLA formulations (Rennova® Elleva vs. Sculptra®). Outcomes included Subject and Physician Global Aesthetic Improvement Scales (S-GAIS, P-GAIS), ultrasonography (USG), skin elasticity, and transepidermal water loss (TEWL) through Day 120. Histological analyses in ten cases assessed skin thickness, inflammation, and crystalline residues.
RESULTS: Both products yielded marked enhancements in skin texture and arm contour with excellent tolerability. S-GAIS scores improved to 2.9 ± 0.67 at Day 120, with no differences between formulations (p > 0.99). P-GAIS scores similarly rose (Rennova® Elleva: 3.2 ± 0.98; Sculptra®: 3.3 ± 0.90; p = 0.86). Ultrasound findings confirmed dermal remodeling in both arms. By Day 120, USG value increased to 957 ± 209 with Rennova® Elleva (p = 0.049) and 938 ± 174 with Sculptra® (p = 0.92), with no between-group difference (p = 0.99). Skin elasticity increased significantly in both arms by Day 90 (Rennova® Elleva: 172 ± 35 to 191 ± 29, p = 0.035; Sculptra®: 165 ± 19 to 177 ± 24, p = 0.041), while TEWL remained stable. Skin thickness rose significantly (Rennova® Elleva: 2.06 ± 0.55 to 2.66 ± 0.53 mm, p = 0.039; Sculptra®: 1.80 ± 0.41 to 2.70 ± 0.69 mm, p = 0.0039), without between-group differences (p = 0.54). Histology showed sparse perivascular lymphocytes and occasional macrophages, with no granulomas or crystalline material.
CONCLUSIONS: This study suggests that both Rennova® Elleva and Sculptra® are effective, well-tolerated PLLA formulations that may be capable of producing meaningful aesthetic and biophysical improvements in upper-arm contour and skin quality within the first 120 days.
METHODS: In this prospective, randomized, blinded split-arm trial, 20 adults received bilateral upper-arm injections with two PLLA formulations (Rennova® Elleva vs. Sculptra®). Outcomes included Subject and Physician Global Aesthetic Improvement Scales (S-GAIS, P-GAIS), ultrasonography (USG), skin elasticity, and transepidermal water loss (TEWL) through Day 120. Histological analyses in ten cases assessed skin thickness, inflammation, and crystalline residues.
RESULTS: Both products yielded marked enhancements in skin texture and arm contour with excellent tolerability. S-GAIS scores improved to 2.9 ± 0.67 at Day 120, with no differences between formulations (p > 0.99). P-GAIS scores similarly rose (Rennova® Elleva: 3.2 ± 0.98; Sculptra®: 3.3 ± 0.90; p = 0.86). Ultrasound findings confirmed dermal remodeling in both arms. By Day 120, USG value increased to 957 ± 209 with Rennova® Elleva (p = 0.049) and 938 ± 174 with Sculptra® (p = 0.92), with no between-group difference (p = 0.99). Skin elasticity increased significantly in both arms by Day 90 (Rennova® Elleva: 172 ± 35 to 191 ± 29, p = 0.035; Sculptra®: 165 ± 19 to 177 ± 24, p = 0.041), while TEWL remained stable. Skin thickness rose significantly (Rennova® Elleva: 2.06 ± 0.55 to 2.66 ± 0.53 mm, p = 0.039; Sculptra®: 1.80 ± 0.41 to 2.70 ± 0.69 mm, p = 0.0039), without between-group differences (p = 0.54). Histology showed sparse perivascular lymphocytes and occasional macrophages, with no granulomas or crystalline material.
CONCLUSIONS: This study suggests that both Rennova® Elleva and Sculptra® are effective, well-tolerated PLLA formulations that may be capable of producing meaningful aesthetic and biophysical improvements in upper-arm contour and skin quality within the first 120 days.